Demographic characteristics of the study cohort
| Characteristic . | Total (n = 128) . | ATG (n = 46) . | PTCy (n = 82) . | P . |
|---|---|---|---|---|
| Transplant center | ||||
| MSKCC | 51 (40%) | 13 (28%) | 38 (46%) | |
| UM SCCC | 77 (60%) | 33 (72%) | 44 (54%) | |
| Age, median (range), y | 60 (21-75) | 55 (21-72) | 60 (21-75) | .05 |
| HLA matching | <.001 | |||
| <7/8 | 26 (20%) | 1 (2.2%) | 25 (30.5%) | |
| 7/8 | 102 (80%) | 45 (98%) | 57 (70%) | |
| Myeloablative intensity | 60 (47%) | 26 (57%) | 34 (41%) | .1 |
| Disease status | .02 | |||
| Complete response | 93 (73%) | 30 (65%) | 63 (77%) | |
| Partial response | 11 (9%) | 7 (15%) | 4 (5%) | |
| Stable disease | 10 (8%) | 1 (2%) | 9 (11%) | |
| No remission | 14 (11%) | 8 (17%) | 6 (7%) | |
| Regimen | .1 | |||
| Busulfan based | 43 (34%) | 18 (39%) | 25 (31%) | |
| Fludarabine/Cy/TBI-200 | 27 (21%) | 5 (11%) | 22 (27%) | |
| Melphalan based | 44 (34%) | 16 (35%) | 28 (34%) | |
| TBI based | 14 (11%) | 7 (15%) | 7 (9%) | |
| HCT comorbidity index | .05 | |||
| 0-2 | 51 (40%) | 13 (28%) | 38 (46%) | |
| ≥3 | 77 (60%) | 33 (72%) | 44 (54%) | |
| Graft source | .008 | |||
| BM | 53 (41%) | 12 (26%) | 41 (50%) | |
| PB | 75 (59%) | 34 (74%) | 41 (50%) | |
| Recipient CMV-seropositive | 92 (72%) | 37 (80%) | 55 (67%) | .1 |
| CD34 dose, median (range) | 2.34 (0.08-10.8) | 2.38 (0.18-9.0) | 2.34 (0.08-10.8) | >.9 |
| CD3 dose, median (range) | 2.30 (0.07-21.8) | 3.81 (0.22-21.8) | 2.12 (0.07-9.5) | .006 |
| CIBMTR risk | .2 | |||
| High | 31 (24%) | 15 (33%) | 16 (20%) | |
| Intermediate | 50 (39%) | 18 (39%) | 32 (39%) | |
| Low | 47 (37%) | 13 (28%) | 34 (41%) | |
| Year of HCT | ||||
| 2010-2013 | 13 (10%) | 13 (28%) | 0 (0%) | |
| 2014-2017 | 38 (30%) | 18 (39%) | 20 (24%) | |
| 2018-2020 | 77 (60%) | 15 (33%) | 62 (76%) | |
| Follow-up, median (range), mo | – | 45.7 (3.7-106) | 27 (6.6-58.7) | |
| Characteristic . | Total (n = 128) . | ATG (n = 46) . | PTCy (n = 82) . | P . |
|---|---|---|---|---|
| Transplant center | ||||
| MSKCC | 51 (40%) | 13 (28%) | 38 (46%) | |
| UM SCCC | 77 (60%) | 33 (72%) | 44 (54%) | |
| Age, median (range), y | 60 (21-75) | 55 (21-72) | 60 (21-75) | .05 |
| HLA matching | <.001 | |||
| <7/8 | 26 (20%) | 1 (2.2%) | 25 (30.5%) | |
| 7/8 | 102 (80%) | 45 (98%) | 57 (70%) | |
| Myeloablative intensity | 60 (47%) | 26 (57%) | 34 (41%) | .1 |
| Disease status | .02 | |||
| Complete response | 93 (73%) | 30 (65%) | 63 (77%) | |
| Partial response | 11 (9%) | 7 (15%) | 4 (5%) | |
| Stable disease | 10 (8%) | 1 (2%) | 9 (11%) | |
| No remission | 14 (11%) | 8 (17%) | 6 (7%) | |
| Regimen | .1 | |||
| Busulfan based | 43 (34%) | 18 (39%) | 25 (31%) | |
| Fludarabine/Cy/TBI-200 | 27 (21%) | 5 (11%) | 22 (27%) | |
| Melphalan based | 44 (34%) | 16 (35%) | 28 (34%) | |
| TBI based | 14 (11%) | 7 (15%) | 7 (9%) | |
| HCT comorbidity index | .05 | |||
| 0-2 | 51 (40%) | 13 (28%) | 38 (46%) | |
| ≥3 | 77 (60%) | 33 (72%) | 44 (54%) | |
| Graft source | .008 | |||
| BM | 53 (41%) | 12 (26%) | 41 (50%) | |
| PB | 75 (59%) | 34 (74%) | 41 (50%) | |
| Recipient CMV-seropositive | 92 (72%) | 37 (80%) | 55 (67%) | .1 |
| CD34 dose, median (range) | 2.34 (0.08-10.8) | 2.38 (0.18-9.0) | 2.34 (0.08-10.8) | >.9 |
| CD3 dose, median (range) | 2.30 (0.07-21.8) | 3.81 (0.22-21.8) | 2.12 (0.07-9.5) | .006 |
| CIBMTR risk | .2 | |||
| High | 31 (24%) | 15 (33%) | 16 (20%) | |
| Intermediate | 50 (39%) | 18 (39%) | 32 (39%) | |
| Low | 47 (37%) | 13 (28%) | 34 (41%) | |
| Year of HCT | ||||
| 2010-2013 | 13 (10%) | 13 (28%) | 0 (0%) | |
| 2014-2017 | 38 (30%) | 18 (39%) | 20 (24%) | |
| 2018-2020 | 77 (60%) | 15 (33%) | 62 (76%) | |
| Follow-up, median (range), mo | – | 45.7 (3.7-106) | 27 (6.6-58.7) | |
MSKCC, Memorial Sloan Kettering Cancer Center; TBI, total body irradiation; UM SCCC, University of Miami Sylvester Comprehensive Cancer Center.